Turnstone Biologics to Participate in Upcoming Investor Conferences - February 21, 2024
21 Feb 2024
Phase 1Cell TherapyImmunotherapy
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences:
TD Cowen 44th Annual Global Health Care Conference
Type:
Presentation and one-on-one investor meetings
Speaker:
Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer
Date:
Wednesday, March 6, 2024
Presentation Time:
2:10pm ET / 11:10am PT
Location:
Boston, MA
Leerink Partners Global Biopharma Conference 2024
Type:
Date:
Location:
One-on-one investor meetings
Wednesday, March 13, 2024
Miami, FL
A live webcast of the presentation may be accessed on the Events page of Turnstone’s Investor Relations website at , where a replay will also be available for a limited period.
Institutional investors interested in meeting with members of Turnstone’s senior management team during the conferences may contact their respective representatives at TD Cowen and Leerink Partners for further information.
About Turnstone
Turnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone’s novel TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TIL, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer and colorectal cancer, and the Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit , and follow us on LinkedIn.
Contact
Ahmed Aneizi
Investor Relations
Turnstone Biologics
(347) 897-5988
ahmed.aneizi@turnstonebio.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.